VNIM
CHRS icon

Vaughan Nelson Investment Management’s Coherus Oncology CHRS Stock Holding History

Vaughan Nelson Investment Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,631,390
Closed -$28.4M – 175
2020
Q4 		$28.4M Buy
+1,631,390
New +$29M 0.33% 103

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vaughan Nelson Investment Management's CHRS Position: Q1 2021 in Review

Vaughan Nelson Investment Management sold out of Coherus Oncology (CHRS) in Q1 2021, closing a stake of 1,631,390 shares — an estimated $28.4M sold.

Vaughan Nelson Investment Management first reported a position in CHRS in Q4 2020 and held it in 1 quarter. The position peaked at $28.4M in Q4 2020. 205 funds tracked by Wall St. Rank hold CHRS as of Q1 2021.

  • Vaughan Nelson Investment Management reported no remaining Coherus Oncology position as of Q1 2021 after selling out during the quarter.
  • Vaughan Nelson Investment Management sold 1,631,390 Coherus Oncology shares in Q1 2021, an estimated $28.4M.
  • Vaughan Nelson Investment Management first reported a position in Coherus Oncology in Q4 2020 and held it in 1 quarter.
  • Vaughan Nelson Investment Management's Coherus Oncology position peaked at $28.4M in Q4 2020.
  • 205 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2021.

Based on Vaughan Nelson Investment Management's 13F filing for Q1 2021, filed 11 May 2021.